{"id":"erenumab-aooe","safety":{"commonSideEffects":[{"rate":"26","effect":"Injection site reactions"},{"rate":"26","effect":"Constipation"},{"rate":"8","effect":"Nasopharyngitis"},{"rate":"5","effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL3833329","moleculeType":"Antibody"},"_dailymed":{"setId":"b998ed05-94b0-47fd-b28f-cddd1e128fd8","title":"AIMOVIG (ERENUMAB-AOOE) INJECTION AIMOVIG (ERENUMAB-AOOE) INJECTION, SOLUTION [AMGEN INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By neutralizing CGRP, erenumab reduces the frequency and severity of migraines. This mechanism represents a novel approach targeting the underlying biology of migraine rather than just treating acute symptoms.","oneSentence":"Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:35.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention in adults"},{"name":"Chronic migraine prevention"}]},"trialDetails":[{"nctId":"NCT06150781","phase":"","title":"Aimovig Pregnancy Exposure Registry","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-01-27","conditions":"Migraine","enrollment":2842},{"nctId":"NCT05684692","phase":"PHASE2","title":"Screening Trial for Pain Relief in Schwannomatosis (STARFISH)","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-08-31","conditions":"Schwannomatosis, Schwannomas, Pain, Chronic","enrollment":40},{"nctId":"NCT04884763","phase":"PHASE2","title":"Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder","status":"COMPLETED","sponsor":"Indiana University","startDate":"2021-11-15","conditions":"Temporomandibular Disorder","enrollment":30},{"nctId":"NCT05162027","phase":"PHASE2","title":"Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2022-05-26","conditions":"Temporomandibular Disorders","enrollment":5},{"nctId":"NCT05142228","phase":"PHASE2","title":"Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2022-05-31","conditions":"Trigeminal Neuropathy","enrollment":5},{"nctId":"NCT04465357","phase":"PHASE4","title":"Efficacy of Erenumab on Functional Impact of Migraine","status":"COMPLETED","sponsor":"Merle Diamond","startDate":"2020-10-22","conditions":"Migraine","enrollment":55},{"nctId":"NCT03912337","phase":"PHASE4","title":"Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-12-04","conditions":"Migraine","enrollment":29}],"_emaApprovals":[],"_faersSignals":[{"count":304,"reaction":"OFF LABEL USE"},{"count":261,"reaction":"DRUG INEFFECTIVE"},{"count":220,"reaction":"MIGRAINE"},{"count":210,"reaction":"DRUG INTOLERANCE"},{"count":185,"reaction":"PAIN"},{"count":179,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":174,"reaction":"HEADACHE"},{"count":168,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":167,"reaction":"ABDOMINAL PAIN UPPER"},{"count":163,"reaction":"BLEPHAROSPASM"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aimovig®","Aimovig"],"phase":"marketed","status":"active","brandName":"erenumab-aooe","genericName":"erenumab-aooe","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Migraine prevention in adults, Chronic migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}